Loading...
Header Logo
Keywords
Last Name
Institution

JOHN W DAVIS

TitleAssociate Professor
InstitutionMD Anderson
DepartmentUrology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Davis JW. Re: Medium-term Oncologic Outcomes in a Large Cohort of Men Treated with Focal or Hemi-ablation Using High-intensity Focused Ultrasonography for Primary Localized Prostate Cancer. Eur Urol. 2020 Apr; 77(4):558. PMID: 32033840.
      View in: PubMed
    2. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 2015 Dec 08; 6(39):41988-96. PMID: 26515605.
      View in: PubMed
    3. Davis JW, Miki T, Akdas A, Watanabe H, Kirkali Z, Wang R, Babaian RJ. The International Prostate Forum introduction and history. Asian J Androl. 2015 Nov-Dec; 17(6):863. PMID: 26112490.
      View in: PubMed
    4. Davis JW. Clever surgeons and challenging study endpoints. BJU Int. 2015 Sep; 116(3):309. PMID: 26260418.
      View in: PubMed
    5. Williams SB, Bozkurt Y, Achim M, Achim G, Davis JW. Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency. BJU Int. 2016 Jan; 117(1):192-8. PMID: 26190197.
      View in: PubMed
    6. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275.
      View in: PubMed
    7. Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 2015 Apr 30; 6(12):10175-94. PMID: 25868388.
      View in: PubMed
    8. Davis JW. Editorial comment for Xu et al. J Endourol. 2015 Feb; 29(2):208-9. PMID: 25358012.
      View in: PubMed
    9. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15. PMID: 25311217.
      View in: PubMed
    10. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219. PMID: 25190691.
      View in: PubMed
    11. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9. PMID: 25023650.
      View in: PubMed
    12. Davis JW. Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU Int. 2014 Sep; 114(3):320-2. PMID: 25146527.
      View in: PubMed
    13. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8. PMID: 24994920.
      View in: PubMed
    14. Davis JW, Kreaden US, Gabbert J, Thomas R. Learning curve assessment of robot-assisted radical prostatectomy compared with open-surgery controls from the premier perspective database. J Endourol. 2014 May; 28(5):560-6. PMID: 24350787.
      View in: PubMed
    15. Davis JW, Choi S. Salvaging failed radiation therapy: does the tumour location permit a less toxic approach? BJU Int. 2013 Aug; 112(3):279-80. PMID: 23826837.
      View in: PubMed
    16. Davis JW, Dasgupta P. A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int. 2013 Feb; 111(2):184-5. PMID: 23356744.
      View in: PubMed
    17. Davis JW, Kamat AM. Lymphadenectomy with robotic cystectomy. Curr Urol Rep. 2013 Feb; 14(1):59-63. PMID: 23138180.
      View in: PubMed
    18. Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int. 2013 May; 111(6):934-40. PMID: 23350937.
      View in: PubMed
    19. Davis JW. What have we learned from the Partin table update? BJU Int. 2013 Jan; 111(1):5. PMID: 23323697.
      View in: PubMed
    20. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9. PMID: 22673704.
      View in: PubMed
    21. Lallas CD, Davis JW. Robotic surgery training with commercially available simulation systems in 2011: a current review and practice pattern survey from the society of urologic robotic surgeons. J Endourol. 2012 Mar; 26(3):283-93. PMID: 22192114.
      View in: PubMed
    22. Kim J, Davis JW. Prostate cancer screening--time to abandon one-size-fits-all approach? JAMA. 2011 Dec 28; 306(24):2717-8. PMID: 22203541.
      View in: PubMed
    23. Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health. 2012 Mar-Apr; 15(2):367-75. PMID: 22433769.
      View in: PubMed
    24. Davis JW, Shah JB, Achim M. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU Int. 2011 Sep; 108(6 Pt 2):993-8. PMID: 21917102.
      View in: PubMed
    25. Davis JW, Achim M, Munsell M, Matin S. Effectiveness of postgraduate training for learning extraperitoneal access for robot-assisted radical prostatectomy. J Endourol. 2011 Aug; 25(8):1363-9. PMID: 21745117.
      View in: PubMed
    26. Davis JW, Shih YC. Trends in the care of radical prostatectomy in the United States from 2003 to 2006. BJU Int. 2011 Jul; 108(1):55. PMID: 21676146.
      View in: PubMed
    27. Mohan R, Beydoun HA, Beydoun MA, Barnes-Eley M, Davis J, Lance R, Schellhammer P. Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study. Qual Life Res. 2011 Jun; 20(5):713-21. PMID: 21132389.
      View in: PubMed
    28. Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011 Jan; 185(1):79-83. PMID: 21074799.
      View in: PubMed
    29. Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, Lynch DF, Davis JW, Shaves ME, Schellhammer PF. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol. 2010 May; 183(5):1822-8. PMID: 20303100.
      View in: PubMed
    30. Davis JW, Castle EP, Pruthi RS, Ornstein DK, Guru KA. Robot-assisted radical cystectomy: an expert panel review of the current status and future direction. Urol Oncol. 2010 Sep-Oct; 28(5):480-6. PMID: 20207174.
      View in: PubMed
    31. Beydoun HA, Mohan R, Beydoun MA, Davis J, Lance R, Schellhammer P. Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer. BJU Int. 2010 Aug; 106(3):334-41. PMID: 20151969.
      View in: PubMed
    32. Mohan R, Beydoun H, Davis J, Lance R, Schellhammer P. Feasibility of using guidelines to choose treatment for prostate cancer. Can J Urol. 2010 Feb; 17(1):4975-84. PMID: 20156376.
      View in: PubMed
    33. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int. 2010 May; 105(10):1386-91. PMID: 19888979.
      View in: PubMed
    34. Davis JW, Kamat A, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized? BJU Int. 2010 Apr; 105(8):1148-54. PMID: 19874300.
      View in: PubMed
    35. Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site hernias occurring after the use of bladeless radially expanding trocars. Urology. 2010 Mar; 75(3):574-80. PMID: 19854489.
      View in: PubMed
    36. Mohan R, Beydoun H, Barnes-Ely ML, Lee L, Davis JW, Lance R, Schellhammer P. Patients' survival expectations before localized prostate cancer treatment by treatment status. J Am Board Fam Med. 2009 May-Jun; 22(3):247-56. PMID: 19429730.
      View in: PubMed
    37. Davis JW. Circulating tumor cell assays for the prognosis of prostate and colon cancers. Expert Opin Med Diagn. 2009 May; 3(3):293-301. PMID: 23488464.
      View in: PubMed
    38. Davis JW. Screening for prostate cancer with serum prostate-specific antigen : what should we recommend while waiting for randomized clinical trial results? Cancer. 2008 Dec 01; 113(11):3067-8. PMID: 18932255.
      View in: PubMed
    39. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009 May; 55(5):1135-43. PMID: 18783876.
      View in: PubMed
    40. Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008 Jun; 179(6):2187-91; discussion 2191. PMID: 18423725.
      View in: PubMed
    41. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008 May; 179(5):1804-9; discussion 1809-10. PMID: 18353398.
      View in: PubMed
    42. Nakanishi H, Wang X, Ochiai A, Trpkov K, Yilmaz A, Donnelly JB, Davis JW, Troncoso P, Babaian RJ. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer. 2007 Dec 01; 110(11):2441-7. PMID: 17932909.
      View in: PubMed
    43. Ochiai A, Shukla A, Davis JW, Fritsche HA, Bhadkamkar V, Babaian RJ. Is there a role for serum human tissue kallikrein in detection of prostate cancer? Urology. 2007 Sep; 70(3):519-22. PMID: 17905108.
      View in: PubMed
    44. Taylor JH, Davis J, Schellhammer P. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer. 2007 Sep; 5(6):386-9. PMID: 17956711.
      View in: PubMed
    45. Schellhammer PF, Diaz JI, Fabrizio MD, Davis JW, Given RW, Main B, Chaganty NR, Hussein R, McKenzie R. Computer modeling technology to assess extracapsular tissue coverage of whole mount sections after retropubic and laparoscopic radical prostatectomy. J Urol. 2007 Oct; 178(4 Pt 1):1301-5. PMID: 17698100.
      View in: PubMed
    46. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007 Jun; 177(6):2151-6; discussion 2156. PMID: 17509305.
      View in: PubMed
    47. Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DF, Shaves M, Schellhammer PF. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J Endourol. 2006 Oct; 20(10):723-31. PMID: 17094746.
      View in: PubMed
    48. Holterman DA, Diaz JI, Blackmore PF, Davis JW, Schellhammer PF, Corica A, Semmes OJ, Vlahou A. Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol. 2006 Mar-Apr; 24(2):97-108. PMID: 16520271.
      View in: PubMed
    49. Ball AJ, Bordeau KP, Davis JW, Given RW, Lynch DF, Fabrizio MD. Modified running vesicourethral anastomosis after robotically assisted laparoscopic radical prostatectomy: use of solitary Lapra-Ty to secure posterior approximation. Urology. 2005 Jul; 66(1):16-8. PMID: 15992902.
      View in: PubMed
    50. Soderdahl DW, Davis JW, Schellhammer PF, Given RW, Lynch DF, Shaves M, Burke BL, Fabrizio MD. Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer. J Endourol. 2005 Apr; 19(3):318-26. PMID: 15865521.
      View in: PubMed
    51. Davis JW, Shaves ME, Schellhammer PF. Contemporary management of prostate cancer with lethal potential. Oncology (Williston Park). 2004 Jun; 18(7):811-20; discussion 820-4, 829-32. PMID: 15255168.
      View in: PubMed
    52. Schellhammer PF, Davis JW. An evaluation of bicalutamide in the treatment of prostate cancer. Clin Prostate Cancer. 2004 Mar; 2(4):213-9. PMID: 15072604.
      View in: PubMed
    53. El-Feel A, Davis JW, Deger S, Roigas J, Wille AH, Schnorr D, Loening S, Hakiem AA, Tuerk IA. Laparoscopic radical prostatectomy--an analysis of factors affecting operating time. Urology. 2003 Aug; 62(2):314-8. PMID: 12893342.
      View in: PubMed
    54. El-Feel A, Davis JW, Deger S, Roigas J, Wille AH, Schnorr D, Hakiem AA, Loening S, Tuerk IA. Positive margins after laparoscopic radical prostatectomy: a prospective study of 100 cases performed by 4 different surgeons. Eur Urol. 2003 Jun; 43(6):622-6. PMID: 12767362.
      View in: PubMed
    55. Qu Y, Adam BL, Thornquist M, Potter JD, Thompson ML, Yasui Y, Davis J, Schellhammer PF, Cazares L, Clements M, Wright GL, Feng Z. Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data. Biometrics. 2003 Mar; 59(1):143-51. PMID: 12762451.
      View in: PubMed
    56. Turk IA, Giessing M, Deger S, Davis JW, Fabrizio MD, Schönberger B, Jordan GH, Loening SA. Laparoscopic live donor right nephrectomy: a new technique with preservation of vascular length. Transplant Proc. 2003 Mar; 35(2):838-40. PMID: 12644158.
      View in: PubMed
    57. Turk IA, Deger S, Morgan WR, Davis JW, Schellhammer PF, Loening SA. Sural nerve graft during laparoscopic radical prostatectomy. Initial experience. Urol Oncol. 2002 Sep-Oct; 7(5):191-4. PMID: 12644215.
      View in: PubMed
    58. Türk IA, Davis JW, Winkelmann B, Deger S, Richter F, Fabrizio MD, Schönberger B, Jordan GH, Loening SA. Laparoscopic dismembered pyeloplasty--the method of choice in the presence of an enlarged renal pelvis and crossing vessels. Eur Urol. 2002 Sep; 42(3):268-75. PMID: 12234512.
      View in: PubMed
    59. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002 Jul 01; 62(13):3609-14. PMID: 12097261.
      View in: PubMed
    60. Davis JW, Pisters LL, Doviak MJ, Donat SM. Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic testicular nonseminomatous germ cell tumor. Urology. 2002 Apr; 59(4):579-83. PMID: 11927318.
      View in: PubMed
    61. Türk I, Davis JW, Deger S, Winkelmann B, Schönberger B, Schellhammer PF, Loening SA. [Laparoscopic radical cystectomy with intracorporeal creation of a continent urinary diversion. Future or present?]. Urologe A. 2002 Mar; 41(2):107-12. PMID: 11993087.
      View in: PubMed
    62. Turk IA, Deger S, Davis JW, Giesing M, Fabrizio MD, Schönberger B, Jordan GH, Loening SA. Laparoscopic live donor right nephrectomy: a new technique with preservation of vascular length. J Urol. 2002 Feb; 167(2 Pt 1):630-3. PMID: 11792933.
      View in: PubMed
    63. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol. 2002 Feb; 167(2 Pt 1):494-500; discussion 501. PMID: 11792905.
      View in: PubMed
    64. Davis JW, Schellhammer PF. Glansectomy: an alternative surgical treatment for Buschke-Lowenstein tumours of the penis. BJU Int. 2001 Oct; 88(6):647. PMID: 11678772.
      View in: PubMed
    65. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol. 2001 Sep; 166(3):947-52. PMID: 11490252.
      View in: PubMed
    66. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001 Aug 15; 61(16):6029-33. PMID: 11507047.
      View in: PubMed
    67. Davis JW, Moriarty RP, Schlossberg SM, Schellhammer PF. Bilateral testicular lymphoma treated with chemotherapy and radiation without orchiectomy: complete response relapsed at 52 months in the vitreous humor. Urology. 2001 Mar; 57(3):555. PMID: 11248646.
      View in: PubMed
    68. Davis JW, Schellhammer PF. Prostatorectal fistula 14 years following brachytherapy for prostate cancer. J Urol. 2001 Jan; 165(1):189. PMID: 11125400.
      View in: PubMed
    69. Davis JW, Kolm P, Wright GL, Kuban D, El-Mahdi A, Schellhammer PF. The durability of external beam radiation therapy for prostate cancer: can it be identified? J Urol. 1999 Sep; 162(3 Pt 1):758-61. PMID: 10458360.
      View in: PubMed
    70. Davis JW, Schellhammer PF, Schlossberg SM. Conservative surgical therapy for penile and urethral carcinoma. Urology. 1999 Feb; 53(2):386-92. PMID: 9933060.
      View in: PubMed
    71. Davis JW, Horstman WG, Schellhammer PF. Segmental testicular ischaemia mimicking testicular tumor. Br J Urol. 1997 Jul; 80(1):187-8. PMID: 9240208.
      View in: PubMed
    72. Davis JW, Schellhammer PF. Collagen mass in prostatic bed after radical retropubic prostatectomy. Urology. 1997 Jul; 50(1):121. PMID: 9218032.
      View in: PubMed
    73. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Canadian Journal of Urology. 23:8271-8277.
    74. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 37:965-971.
    75. Quality of Life. 461-470.
    76. Robot-assisted pelvic lymphadenectomy. 93-101.
    77. Editorial Comment. Journal of Urology. 178:477.
    78. Genitourinary cancer survivorship management. 95-124.
    79. Complications after robot-assisted radical cystectomy with urinary diversion. 409-417.
    80. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    81. Prostate cancer early detection, Version 2.2016. JNCCN Journal of the National Comprehensive Cancer Network. 14:509-519.
    82. Correlation of histomorphologic findings and partial neurovascular bundle preservation during laparoscopic and robotic radical prostatectomy. Journal of Robotic Surgery. 7:1-8.
    83. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications. 7.
    84. Neoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity. Clinical Genitourinary Cancer. 14:130-138.
    85. Prostate cancer early detection, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network. 13:1534-1561.
    86. Recommendations on use of prostate-specific antigen for prostate cancer screening - Reply [3]. JAMA - Journal of the American Medical Association. 307:1373.
    87. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 6:10175-10194.
    88. Risk of hospitalisation after primary treatment for prostate cancer. BJU International.
    89. Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investigative and Clinical Urology. 57:S155-S164.
    90. Bilateral testicular lymphoma treated with chemotherapy and radiation without orchiectomy. Urology. 57.
    91. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 18:276-280.
    92. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 6:41988-41996.
    93. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU International. 117:469-477.
    94. Case series. British Journal of Urology. 80:307.
    95. Radical Retropubic Prostatectomy. 279-287.
    96. The implications of ageing and life expectancy in prostate cancer treatment. Nature Reviews Urology. 13:289-295.
    97. The International Prostate Forum introduction and history. Asian Journal of Andrology. 17:863.
    98. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. International Braz J Urol. 37:118.
    DAVIS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description